Latest News about LTRN
Recent news which mentions LTRN
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Friday
October 28, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
October 27, 2022
From Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 12, 2022
From Benzinga
Treating Pediatric Cancer? How Lantern Pharma Hopes To Improve The Lives Of Pediatric Cancer Patients During Childhood Cancer Awareness Month
September 15, 2022
Tickers
LTRN
From Benzinga
Lantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer Candidate
September 14, 2022
Tickers
LTRN
From Benzinga
Lantern Pharma's New Phase 2 Clinical Trial –Harmonic™ — Approved for Launch by the FDA
July 19, 2022
Tickers
LTRN
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Earnings Scheduled For March 10, 2022
March 10, 2022
From Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
March 06, 2022
From Benzinga
Benzinga Announces This Week's All Access Guests
January 27, 2022
From Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 24, 2022
From Benzinga
Lantern Pharma's LP-184 Receives Rare Pediatric, Orphan Drug Tags For Rare Form Of Cancer
January 24, 2022
Tickers
LTRN
From Benzinga
Earnings Scheduled For November 1, 2021
November 01, 2021
From Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
October 08, 2021
From Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
October 07, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
October 07, 2021
From Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
October 06, 2021
From Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
October 05, 2021
From Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
September 29, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.